ECSP12011695A - Derivados de (tio) morfolina como moduladores de s1p - Google Patents
Derivados de (tio) morfolina como moduladores de s1pInfo
- Publication number
- ECSP12011695A ECSP12011695A ECSP12011695A ECSP12011695A EC SP12011695 A ECSP12011695 A EC SP12011695A EC SP12011695 A ECSP12011695 A EC SP12011695A EC SP12011695 A ECSP12011695 A EC SP12011695A
- Authority
- EC
- Ecuador
- Prior art keywords
- alkyl
- optionally substituted
- atoms
- halogen
- fluoro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/6533—Six-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a derivados de (tio)morfolina que tienen la fórmula (I) (I)en dondeR1 se selecciona de ciano, alquinilo (2-4C), alquilo (1-4C), cicloalquilo (3-6C), cicloalquenilo (4-6C),bicicloalquilo (6-8C),, grupo bicíclico (8-10C), cada uno sustituido en forma opcional con alquilo (1-4C),fenilo, bifenilo, naftilo, cada uno sustituido en forma opcional con uno o más sustituyentes se selecciona en forma independiente de halógeno, alquilo (C1-4C) sustituido en forma opcional con uno o más átomos de fluoro, alquinilo (2-4C), alcoxi (C1-4C) sustituido en forma opcional con uno o más átomos de fluoro, amino, dialquilamino (C1-4C) , SO2 alquilo (1-4C), CO alquilo (1-4C), CO O alquilo (1-4C), NH-CO alquilo (C1-4C) y cicloalquilo (3-6C), fenilo sustituido con fenoxi, bencilo, benciloxi, feniletilo o heterociclo monocíclico, cada uno sustituido en forma opcional con alquilo (1-4C), heterociclo monocíclico sustituido en forma opcional con halógeno, alquilo (C1-4C) o con fenilo sustituido en forma opcional con alquilo (1-4C), heterociclo bicíclico sustituido en forma opcional con alquilo (C1-4C);A se selecciona de -CO-O-, -O-CO-, -NH-CO-, -CO-NH, -C=C-, -CCH3-O- y el grupo de enlace -Y-(CH2)n-X- en donde Y está unido a R1 y se selecciona de un enlace, -O-, -S-, -SO-, -SO2-, -CH2-O-, CO-, -O-CO-, CO-O-, -CO-NH-, -NH-CO-, -C=C- y C?C- ; n es un número entero desde 1 hasta 10; y X está unido al grupo fenileno / piridilo y se selecciona de un enlace, -O-, S-, -SO-, -SO2-, -NH, -CO-, -C=C- y C?C-;la estructura del anillo B contiene en forma opcional un átomo de nitrógeno;R2 es H, alquilo (C1-4C) sustituido en forma opcional con uno o más átomos de fluoro, alcoxi (C1-4C) sustituido en forma opcional con uno o más átomos de fluoro, o halógeno; yR3 es alquileno (1-4C)-R5 en donde el grupo alquileno puede estar sustituido con (CH2)2 para formar un resto ciclopropilo o uno o dos átomos de halógeno, o R3 es cicloalquileno (3-6C)-R5 o -CO-CH2-R5, en donde R5 es -OH, -PO3H2, OPO3H2, COOH, -COOalquilo (C1-4C) o tetrazol-5-ilo;R4 es H o alquilo (C1-4C);R6 es uno o más sustituyentes se selecciona en forma independiente de H, alquilo (C1-4C) o oxo;W es -O-, -S-, -SO- o -SO2-;o una sal, un solvato o un hidrato aceptables desde el punto de vista farmacéutico de los anteriores; con la salvedad de que el derivado que tiene la fórmula (I) no sea 2 (4 etilfenil) 4 morfolinoetanol o 4 [4 (2 hidroxietil) 2 morfolinil]bencenacetonitriloo una sal, un solvato o un hidrato aceptables desde el punto de vista farmacéutico de los anteriores.Los compuestos de la invención tienen afinidad por los receptores de S1P y pueden usarse en el tratamiento, alivio o prevención de enfermedades y dolencias mediadas por el receptor S1P.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23851809P | 2009-08-31 | 2009-08-31 | |
| EP09169075 | 2009-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP12011695A true ECSP12011695A (es) | 2012-03-30 |
Family
ID=41361253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP12011695 ECSP12011695A (es) | 2009-08-31 | 2012-02-27 | Derivados de (tio) morfolina como moduladores de s1p |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9045441B2 (es) |
| EP (1) | EP2473490B1 (es) |
| JP (1) | JP5933436B2 (es) |
| KR (1) | KR101767882B1 (es) |
| CN (1) | CN102548976B (es) |
| AR (1) | AR077969A1 (es) |
| AU (1) | AU2010288477B8 (es) |
| CA (1) | CA2772169C (es) |
| CR (1) | CR20120153A (es) |
| DO (1) | DOP2012000053A (es) |
| EC (1) | ECSP12011695A (es) |
| ES (1) | ES2452550T3 (es) |
| IL (1) | IL218208A (es) |
| MX (1) | MX2012002534A (es) |
| NZ (1) | NZ598300A (es) |
| PE (1) | PE20121280A1 (es) |
| PL (1) | PL2473490T3 (es) |
| RU (1) | RU2557233C2 (es) |
| SG (1) | SG178902A1 (es) |
| TW (1) | TW201113263A (es) |
| UA (1) | UA106994C2 (es) |
| UY (1) | UY32858A (es) |
| WO (1) | WO2011023795A1 (es) |
| ZA (1) | ZA201201446B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR077969A1 (es) | 2009-08-31 | 2011-10-05 | Abbott Healthcare Products Bv | Derivados de (tio)morfolina comomoduladores de s1p |
| TW201206893A (en) | 2010-07-09 | 2012-02-16 | Abbott Healthcare Products Bv | Bisaryl (thio) morpholine derivatives as S1P modulators |
| TWI522361B (zh) | 2010-07-09 | 2016-02-21 | 艾伯維公司 | 作為s1p調節劑的稠合雜環衍生物 |
| TW201643169A (zh) | 2010-07-09 | 2016-12-16 | 艾伯維股份有限公司 | 作為s1p調節劑的螺-哌啶衍生物 |
| US8802673B2 (en) | 2011-03-24 | 2014-08-12 | Hoffmann-La Roche Inc | Heterocyclic amine derivatives |
| US9029370B2 (en) * | 2011-06-10 | 2015-05-12 | Hoffmann-La Roche Inc. | Substituted benzamide derivatives |
| WO2014072257A1 (en) * | 2012-11-07 | 2014-05-15 | F. Hoffmann-La Roche Ag | Pyrazine derivatives |
| ES2636596T3 (es) * | 2012-11-20 | 2017-10-06 | Biogen Ma Inc. | Agentes moduladores de S1P y/o ATX |
| CN105949142B (zh) * | 2016-05-21 | 2018-03-27 | 南华大学 | 具有抗抑郁活性的单一手性化合物及其制备方法和应用 |
| JP2018095631A (ja) * | 2016-12-14 | 2018-06-21 | 東ソー株式会社 | フェノール誘導体製造方法 |
| US20180230105A1 (en) | 2017-01-13 | 2018-08-16 | Regents Of The University Of Minnesota | Therapeutic compounds |
| US11535632B2 (en) | 2019-10-31 | 2022-12-27 | ESCAPE Bio, Inc. | Solid forms of an S1P-receptor modulator |
| CN118251382A (zh) * | 2021-11-08 | 2024-06-25 | 豪夫迈·罗氏有限公司 | 芳硝基化合物的催化氢化 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH072848A (ja) | 1993-04-23 | 1995-01-06 | Sankyo Co Ltd | モルホリンおよびチオモルホリン誘導体 |
| JP4152002B2 (ja) * | 1996-08-27 | 2008-09-17 | 興和創薬株式会社 | ２−フェニルモルホリン−５−オン誘導体およびそれを含む医薬組成物 |
| US6380387B1 (en) | 1999-12-06 | 2002-04-30 | Hoffmann-La Roche Inc. | 4-Pyrimidinyl-n-acyl-l phenylalanines |
| JP3974781B2 (ja) | 2000-04-21 | 2007-09-12 | 塩野義製薬株式会社 | 抗癌作用を有するオキサジアゾール誘導体 |
| MXPA05013464A (es) | 2003-06-12 | 2006-03-17 | Btg Int Ltd | Hidroxilamina ciclica como compuestos psicoactivos. |
| RU2390519C2 (ru) * | 2003-08-29 | 2010-05-27 | Оно Фармасьютикал Ко., Лтд. | Соединение, способное к связыванию с рецептором s1p, и его фармацевтическое применение |
| US7550485B2 (en) | 2003-10-14 | 2009-06-23 | Wyeth | Substituted N-heterocycle derivatives and methods of their use |
| GB0329498D0 (en) | 2003-12-19 | 2004-01-28 | Novartis Ag | Organic compounds |
| TW200538433A (en) * | 2004-02-24 | 2005-12-01 | Irm Llc | Immunosuppressant compounds and compositiions |
| AU2005238296A1 (en) * | 2004-04-30 | 2005-11-10 | Warner-Lambert Company Llc | Substituted morpholine compounds for the treatment of central nervous system disorders |
| GB0409744D0 (en) | 2004-04-30 | 2004-06-09 | Pfizer Ltd | Novel compounds |
| JP2008517915A (ja) * | 2004-10-22 | 2008-05-29 | メルク エンド カムパニー インコーポレーテッド | Ｓ１ｐ受容体アゴニストとしての２−（アリール）アザシクリルメチルカルボキシレート、スルホネート、ホスホネート、ホスフィネート及びヘテロ環 |
| WO2006047159A1 (en) * | 2004-10-22 | 2006-05-04 | Agrinomics Llc | Generation of plants with altered oil content |
| KR101079914B1 (ko) | 2006-01-27 | 2011-11-04 | 에프. 호프만-라 로슈 아게 | 중추신경계 장애를 위한 4-이미다졸 유도체의 용도 |
| JP2009524617A (ja) | 2006-01-27 | 2009-07-02 | エフ．ホフマン−ラ ロシュ アーゲー | 置換２−イミダゾール又はイミダゾリン誘導体の使用 |
| BRPI0708337A2 (pt) * | 2006-02-28 | 2011-05-24 | Helicon Therapeutics Inc | pipirazinas terapêutica como inibidores pde4 |
| CA2662091A1 (en) * | 2006-09-08 | 2008-03-13 | Novartis Ag | N-biaryl (hetero) arylsulphonamide derivatives useful in the treatment of diseases mediated by lymphocytes interactions |
| CN101562977A (zh) * | 2006-12-15 | 2009-10-21 | 艾博特公司 | 新的二唑化合物 |
| BRPI0806932A2 (pt) * | 2007-02-02 | 2014-05-06 | Novartis Ag | Antagonista do receptor s1p1 de cromeno |
| AR077969A1 (es) | 2009-08-31 | 2011-10-05 | Abbott Healthcare Products Bv | Derivados de (tio)morfolina comomoduladores de s1p |
| CN101812058B (zh) | 2010-04-13 | 2012-03-21 | 湖南大学 | 吲哚美辛2-芳基吗啉乙酯及其制备方法与应用 |
-
2010
- 2010-08-26 AR ARP100103116A patent/AR077969A1/es unknown
- 2010-08-26 UY UY0001032858A patent/UY32858A/es not_active Application Discontinuation
- 2010-08-27 ES ES10745659.2T patent/ES2452550T3/es active Active
- 2010-08-27 NZ NZ598300A patent/NZ598300A/xx not_active IP Right Cessation
- 2010-08-27 PL PL10745659T patent/PL2473490T3/pl unknown
- 2010-08-27 CA CA2772169A patent/CA2772169C/en not_active Expired - Fee Related
- 2010-08-27 US US13/393,497 patent/US9045441B2/en not_active Expired - Fee Related
- 2010-08-27 TW TW099128939A patent/TW201113263A/zh unknown
- 2010-08-27 MX MX2012002534A patent/MX2012002534A/es active IP Right Grant
- 2010-08-27 JP JP2012526075A patent/JP5933436B2/ja not_active Expired - Fee Related
- 2010-08-27 EP EP10745659.2A patent/EP2473490B1/en active Active
- 2010-08-27 PE PE2012000276A patent/PE20121280A1/es not_active Application Discontinuation
- 2010-08-27 UA UAA201203923A patent/UA106994C2/uk unknown
- 2010-08-27 SG SG2012013793A patent/SG178902A1/en unknown
- 2010-08-27 WO PCT/EP2010/062552 patent/WO2011023795A1/en not_active Ceased
- 2010-08-27 AU AU2010288477A patent/AU2010288477B8/en not_active Ceased
- 2010-08-27 RU RU2012112477/04A patent/RU2557233C2/ru not_active IP Right Cessation
- 2010-08-27 KR KR1020127008115A patent/KR101767882B1/ko not_active Expired - Fee Related
- 2010-08-27 CN CN201080042681.8A patent/CN102548976B/zh not_active Expired - Fee Related
-
2012
- 2012-02-20 IL IL218208A patent/IL218208A/en not_active IP Right Cessation
- 2012-02-27 ZA ZA2012/01446A patent/ZA201201446B/en unknown
- 2012-02-27 EC ECSP12011695 patent/ECSP12011695A/es unknown
- 2012-02-29 DO DO2012000053A patent/DOP2012000053A/es unknown
- 2012-03-27 CR CR20120153A patent/CR20120153A/es unknown
-
2015
- 2015-03-30 US US14/673,614 patent/US9273017B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2012000053A (es) | Derivados de (tio) morfolina como moduladores de s1p | |
| AR102094A1 (es) | Inhibidores de proteínas kras con una mutación g12c | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| MX2019015226A (es) | Inhibidores de quinasa alk2 que contienen imidazol. | |
| BR112019008415A2 (pt) | composto de piridona e inibidor de c-met, composição farmacêutica e uso dos mesmos | |
| BR112014019478A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmacologicamente aceitável do mesmo, formulação inibidor do canal de sódio, métodos para tratamento e/ou prevenção de dor e de uma doença. | |
| AR103828A1 (es) | INHIBIDORES DEL FACTOR TRANSFORMADOR DEL CRECIMIENTO b | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| AR051431A1 (es) | Compuestos de pirazolina substituidos, su preparacion y su uso como medicamentos | |
| AR065844A1 (es) | Derivados de 8-(heteroarilmetoxi)quinolina, moduladores selectivos de receptores de bradiquinina (bk) b2, composiciones farmaceuticas que los contienen y usos en terapia. | |
| MX2024007312A (es) | Inhibidor doble de pde3/4 heterociclico condensado triciclico y uso de este. | |
| AR068509A1 (es) | Antagosnistas del receptor de bradiquinina b1 | |
| BR112015023705A2 (pt) | composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia) | |
| AR101177A1 (es) | Inhibidores de la syk | |
| AR083879A1 (es) | Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos | |
| AR094100A1 (es) | DERIVADOS CARBAMATO DE CICLOHEXILO Y QUINUCLIDINILO QUE TIENEN ACTIVIDAD COMO AGONISTAS b2 ADRENERGICOS Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| BR112015029401A2 (pt) | derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças | |
| AR112283A1 (es) | Uso de derivados de aminoalquilbenzotiazepina | |
| BR122018070508B8 (pt) | derivados de arilamida triazol-substituída e seu uso | |
| PE20181017A1 (es) | Compuestos heteroarilo y su uso como farmacos terapeuticos | |
| AR120652A1 (es) | Antagonistas de sstr5 | |
| MX2020003993A (es) | Derivados de bencimidazol y sus usos. | |
| PY1978496A (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
| BR112022006394A2 (pt) | Derivados heterocíclicos, composições farmacêuticas e seu uso no tratamento ou melhora do câncer | |
| BR112015016184A2 (pt) | derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral |